Efficacy and safety of Bosutinib in Patient with Chronic myeloid
leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report
- Abdullah Mohammad Arshad
, - mohamed yassin
![](https://d197for5662m48.cloudfront.net/assets/icons/omniauth/orcid-ca37582cd91a671ed5cec57770e0e96c01b4b79b8b5b75d8598fc1ddac18c974.svg)
Abstract
Bosutinib is approved as first line therapy for treatment of chronic
phase CML and also in patients who are either resistant or intolerant to
previous TKI. We present a 59 year old male who was intolerant to 2 TKI
but showed excellent hematological and major molecular response to
Bosutinib.